



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation

Citation for published version:

kConFab/AOCS Investigators, Ghossaini, M, French, JD, Michailidou, K, Nord, S, Beesley, J, Canisus, S, Hillman, KM, Kaufmann, S, Sivakumaran, H, Moradi Marjaneh, M, Lee, JS, Dennis, J, Bolla, MK, Wang, Q, Dicks, E, Milne, RL, Hopper, JL, Southey, MC, Schmidt, MK, Broeks, A, Muir, K, Lophatananon, A, Fasching, PA, Beckmann, MW, Fletcher, O, Johnson, N, Sawyer, EJ, Tomlinson, I, Burwinkel, B, Marme, F, Guénel, P, Truong, T, Bojesen, SE, Flyger, H, Benitez, J, González-Neira, A, Alonso, MR, Pita, G, Neuhausen, SL, Anton-Culver, H, Brenner, H, Arndt, V, Meindl, A, Schmutzler, RK, Brauch, H, Hamann, U, Tessier, DC, Vincent, D, Nevanlinna, H & Figueroa, J 2016, 'Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation', *American Journal of Human Genetics*, vol. 99, no. 4, pp. 903-911. <https://doi.org/10.1016/j.ajhg.2016.07.017>

Digital Object Identifier (DOI):

[10.1016/j.ajhg.2016.07.017](https://doi.org/10.1016/j.ajhg.2016.07.017)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

American Journal of Human Genetics

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through *FGF10* and *MRPS30* Regulation

Maya Ghoussaini,^{1,98} Juliet D. French,^{2,98} Kyriaki Michailidou,^{3,4} Silje Nord,⁵ Jonathan Beesley,² Sander Canisus,⁶ Kristine M. Hillman,² Susanne Kaufmann,² Haran Sivakumaran,² Mahdi Moradi Marjaneh,² Jason S. Lee,² Joe Dennis,³ Manjeet K. Bolla,³ Qin Wang,³ Ed Dicks,¹ Roger L. Milne,^{7,8} John L. Hopper,⁸ Melissa C. Southey,⁹ Marjanka K. Schmidt,⁶ Annegien Broeks,⁶ Kenneth Muir,^{10,11} Artitaya Lophatananon,^{10,11} Peter A. Fasching,^{12,13} Matthias W. Beckmann,¹² Olivia Fletcher,^{14,15} Nichola Johnson,^{14,15} Elinor J. Sawyer,¹⁶ Ian Tomlinson,¹⁷ Barbara Burwinkel,^{18,19} Frederik Marme,^{18,20} Pascal Guénel,²¹ Thérèse Truong,²¹ Stig E. Bojesen,^{22,23,24} Henrik Flyger,²⁵ Javier Benitez,^{26,27} Anna González-Neira,²⁶ M. Rosario Alonso,²⁸ Guillermo Pita,²⁸ Susan L. Neuhausen,²⁹ Hoda Anton-Culver,³⁰ Hermann Brenner,^{31,32,33} Volker Arndt,³¹ Alfons Meindl,³⁴ Rita K. Schmutzler,^{35,36,37} Hiltrud Brauch,^{32,38,39} Ute Hamann,⁴⁰ Daniel C. Tessier,⁴¹ Daniel Vincent,⁴¹ Heli Nevanlinna,⁴² Sofia Khan,⁴² Keitaro Matsuo,⁴³ Hidemi Ito,⁴⁴ Thilo Dörk,⁴⁵ Natalia V. Bogdanova,^{45,46} Annika Lindblom,⁴⁷ Sara Margolin,⁴⁸ Arto Mannermaa,^{49,50,51}

(Author list continued on next page)

Genome-wide association studies (GWASs) have revealed increased breast cancer risk associated with multiple genetic variants at 5p12. Here, we report the fine mapping of this locus using data from 104,660 subjects from 50 case-control studies in the Breast Cancer Association Consortium (BCAC). With data for 3,365 genotyped and imputed SNPs across a 1 Mb region (positions 44,394,495–45,364,167; NCBI build 37), we found evidence for at least three independent signals: the strongest signal, consisting of a single SNP rs10941679, was associated with risk of estrogen-receptor-positive (ER⁺) breast cancer (per-g allele OR ER⁺ = 1.15; 95% CI 1.13–1.18; p = 8.35 × 10⁻³⁰). After adjustment for rs10941679, we detected signal 2, consisting of 38 SNPs more strongly associated with ER-negative (ER⁻) breast cancer (lead SNP rs6864776: per-a allele OR ER⁻ = 1.10; 95% CI 1.05–1.14; p conditional = 1.44 × 10⁻¹²), and a single signal 3 SNP (rs200229088: per-t allele OR ER⁺ = 1.12; 95% CI 1.09–1.15; p conditional = 1.12 × 10⁻⁰⁵). Expression quantitative trait locus analysis in normal breast tissues and breast tumors showed that the g (risk) allele of rs10941679 was associated with increased expression of *FGF10* and *MRPS30*. Functional assays demonstrated that SNP rs10941679 maps to an enhancer element that physically interacts with the *FGF10* and *MRPS30* promoter regions in breast cancer cell lines. *FGF10* is an oncogene that binds to FGFR2 and is overexpressed in ~10% of human breast cancers, whereas *MRPS30* plays a key role in apoptosis. These data suggest that the strongest signal of association at 5p12 is mediated through coordinated activation of *FGF10* and *MRPS30*, two candidate genes for breast cancer pathogenesis.

Strong evidence for the existence of a breast cancer (MIM: 114480) susceptibility locus at 5p12 has been observed through a GWAS in Iceland (SNP rs7703618),¹ in the Breast Cancer Association Consortium (BCAC; SNP rs981782, 371 Kb centromeric),² and in the Cancer Genetic Markers of Susceptibility study (CGEMS; SNP rs4866929; 352 Kb

¹Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK; ²Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia; ³Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK; ⁴Department of Electron Microscopy/Molecular Pathology, The Cyprus Institute of Neurology and Genetics, Nicosia 1683, Cyprus; ⁵Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, 0310 Oslo, Norway; ⁶Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, the Netherlands; ⁷Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, VIC 3004, Australia; ⁸Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC 3010, Australia; ⁹Department of Pathology, The University of Melbourne, Melbourne, VIC 3010, Australia; ¹⁰Institute of Population Health, University of Manchester, Manchester M13 9PL, UK; ¹¹Division of Health Sciences, Warwick Medical School, Warwick University, Coventry CV4 7AL, UK; ¹²Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany; ¹³David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, CA 90095, USA; ¹⁴Toby Robins Breast Cancer Now Research Centre, The Institute of Cancer Research, London SW3 6JB, UK; ¹⁵Division of Breast Cancer Research, The Institute of Cancer Research, London SW7 3RP, UK; ¹⁶Research Oncology, Guy's Hospital, King's College London, London SE1 9RT, UK; ¹⁷Wellcome Trust Centre for Human Genetics and Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford OX3 7BN, UK; ¹⁸Department of Obstetrics and Gynecology, University of Heidelberg, 69120 Heidelberg, Germany; ¹⁹Molecular Epidemiology Group, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; ²⁰National Center for Tumor Diseases, University of Heidelberg, 69120 Heidelberg, Germany; ²¹Cancer & Environment Group, Center for Research in Epidemiology and Population Health (CESP), INSERM, University Paris-Sud, University Paris-Saclay, 94807 Villejuif, France; ²²Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark; ²³Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark; ²⁴Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark;

(Affiliations continued on next page)

© 2016 The Author(s). This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Veli-Matti Kosma,^{49,50,51} kConFab/AOCS Investigators, Anna H. Wu,⁵² David Van Den Berg,⁵² Diether Lambrechts,^{53,54} Giuseppe Floris,⁵⁵ Jenny Chang-Claude,^{56,57} Anja Rudolph,⁵⁶ Paolo Radice,⁵⁸ Monica Barile,⁵⁹ Fergus J. Couch,⁶⁰ Emily Hallberg,⁶¹ Graham G. Giles,^{7,8} Christopher A. Haiman,⁵² Loic Le Marchand,⁶² Mark S. Goldberg,^{63,64} Soo H. Teo,^{65,66} Cheng Har Yip,⁶⁶ Anne-Lise Borresen-Dale,⁵ NBCS Collaborators, Wei Zheng,⁶⁷ Qiuyin Cai,⁶⁷ Robert Winqvist,^{68,69} Katri Pylkäs,^{68,69} Irene L. Andrulis,^{70,71} Peter Devilee,^{72,73} Rob A.E.M. Tollenaar,⁷⁴ Montserrat García-Closas,⁷⁵ Jonine Figueroa,^{75,76} Per Hall,⁷⁷ Kamila Czene,⁷⁷ Judith S. Brand,⁷⁷ Hatef Darabi,⁷⁷ Mikael Eriksson,⁷⁷ Maartje J. Hoening,⁷⁸ Linetta B. Koppert,⁷⁹ Jingmei Li,⁷⁷ Xiao-Ou Shu,⁶⁷ Ying Zheng,⁸⁰ Angela Cox,⁸¹ Simon S. Cross,⁸² Mitul Shah,¹ Valerie Rhenius,¹ Ji-Yeob Choi,^{83,84} Daehee Kang,^{83,84,85} Mikael Hartman,^{86,87} Kee Seng Chia,⁸⁶ Maria Kabisch,⁴⁰ Diana Torres,^{40,88} Craig Luccarini,¹ Don M. Conroy,¹ Anna Jakubowska,⁸⁹

(Author list continued on next page)

centromeric; $r^2 = 0.18$).³ A subsequent study, using 22 SNPs in ~5,000 case subjects and ~33,000 control subjects of European ancestry, reported that risk at this locus could be explained by two SNPs: rs4415084 and rs10941679.⁴ More recently, a BCAC study confirmed that rs10941679 was associated with risk of lower-grade, progesterone receptor (*PGR* [MIM: 607311])-positive breast cancer tumors.⁵

Here, we report the comprehensive fine-scale mapping of this locus in 104,660 subjects from 50 case-control studies participating in BCAC, including 41 studies from populations of European ancestry and nine of East Asian ancestry, and we explore the functional mechanisms underlying the associations in this region. Genotyping was conducted with the COGS array, a custom array

comprising approximately 200,000 SNPs.⁶ After quality-control exclusions, we analyzed data from 48,155 case subjects and 43,612 control subjects of European ancestry and 6,269 case subjects and 6,624 control subjects of Asian ancestry. Estrogen receptor (*ESR1* [MIM: 133430]) status of the primary tumor was available for 27,748 European and 4,997 Asian case subjects; of these, 7,646 (22%) European and 1,623 (32%) Asian case subjects were ER⁻.

We examined a 1 Mb region (positions 44,394,495–45,364,167; NCBI build 37 assembly) in which the 1000 Genomes Project cataloged 1,811 variants (March 2010 Pilot version 60 CEU project data). We aimed to genotype all 628 SNPs with minor allele frequency (MAF) > 2% and correlated with rs981782 and rs10941679 at $r^2 > 0.1$ (n = 424), plus a set of SNPs designed to tag all remaining

²⁵Department of Breast Surgery, Herlev and Gentofte Hospital, Copenhagen University Hospital, 2730 Herlev, Denmark; ²⁶Human Cancer Genetics Program, Spanish National Cancer Research Centre, 28029 Madrid, Spain; ²⁷Centro de Investigación en Red de Enfermedades Raras, 46010 Valencia, Spain; ²⁸Human Genotyping-CEGEN Unit, Human Cancer Genetic Program, Spanish National Cancer Research Centre, 28029 Madrid, Spain; ²⁹Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA 92697, USA; ³⁰Department of Epidemiology, University of California Irvine, Irvine, CA 92697, USA; ³¹Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; ³²German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; ³³Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), 69120 Heidelberg, Germany; ³⁴Division of Gynaecology and Obstetrics, Technische Universität München, 81675 Munich, Germany; ³⁵Center for Hereditary Breast and Ovarian Cancer, University Hospital of Cologne, 50931 Cologne, Germany; ³⁶Center for Integrated Oncology (CIO), University Hospital of Cologne, 50937 Cologne, Germany; ³⁷Center for Molecular Medicine Cologne (CMC), University of Cologne, 50931 Cologne, Germany; ³⁸Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, 70376 Stuttgart, Germany; ³⁹University of Tübingen, 72074 Tübingen, Germany; ⁴⁰Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; ⁴¹McGill University and Génome Québec Innovation Centre, Montréal, QC H3A 0G1, Canada; ⁴²Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, 00029 Helsinki, Finland; ⁴³Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan; ⁴⁴Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan; ⁴⁵Gynaecology Research Unit, Hannover Medical School, 30625 Hannover, Germany; ⁴⁶Department of Radiation Oncology, Hannover Medical School, 30625 Hannover, Germany; ⁴⁷Department of Molecular Medicine and Surgery, Karolinska Institutet, 17177 Stockholm, Sweden; ⁴⁸Department of Oncology-Pathology, Karolinska Institutet, 17177 Stockholm, Sweden; ⁴⁹Cancer Center of Eastern Finland, University of Eastern Finland, 70211 Kuopio, Finland; ⁵⁰Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, 70211 Kuopio, Finland; ⁵¹Imaging Center, Department of Clinical Pathology, Kuopio University Hospital, 70210 Kuopio, Finland; ⁵²Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; ⁵³Vesalius Research Center, VIB, 3000 Leuven, Belgium; ⁵⁴Laboratory for Translational Genetics, Department of Oncology, University of Leuven, 3000 Leuven, Belgium; ⁵⁵University Hospital Gashuisberg, 3000 Leuven, Belgium; ⁵⁶Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; ⁵⁷University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; ⁵⁸Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS (Istituto Di Ricovero e Cura a Carattere Scientifico) Istituto Nazionale dei Tumori (INT), 20133 Milan, Italy; ⁵⁹Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, 20141 Milan, Italy; ⁶⁰Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA; ⁶¹Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA; ⁶²University of Hawaii Cancer Center, Honolulu, HI 96813, USA; ⁶³Department of Medicine, McGill University, Montreal, QC H3G 2M1, Canada; ⁶⁴Division of Clinical Epidemiology, Royal Victoria Hospital, McGill University, Montreal, QC H3A 1A8, Canada; ⁶⁵Cancer Research Initiatives Foundation, Subang Jaya, 47500 Selangor, Malaysia; ⁶⁶Breast Cancer Research Unit, Cancer Research Institute, University Malaya Medical Centre, 59100 Kuala Lumpur, Malaysia; ⁶⁷Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37203, USA; ⁶⁸Laboratory of Cancer Genetics and Tumor Biology, Cancer Research and Translational Medicine, Biocenter Oulu, University of Oulu, 90220 Oulu, Finland; ⁶⁹Laboratory of Cancer Genetics and Tumor Biology, Northern Finland Laboratory Centre Oulu, 90220 Oulu, Finland; ⁷⁰Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada; ⁷¹Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada; ⁷²Department of Pathology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands; ⁷³Department of Human Genetics, Leiden University Medical Center, 2300 RC Leiden, the Netherlands; ⁷⁴Department of Surgery, Leiden University Medical Center, 2300 RC Leiden, the Netherlands; ⁷⁵Division of Cancer Epidemiology and

(Affiliations continued on next page)

Jan Lubinski,⁸⁹ Suleeporn Sangrajrang,⁹⁰ Paul Brennan,⁹¹ Curtis Olswold,⁶² Susan Slager,⁶² Chen-Yang Shen,^{92,93} Ming-Feng Hou,⁹⁴ Anthony Swerdlow,^{15,95} Minouk J. Schoemaker,⁹⁵ Jacques Simard,⁹⁶ Paul D.P. Pharoah,^{1,3} Vessela Kristensen,^{5,97} Georgia Chenevix-Trench,² Douglas F. Easton,^{1,3} Alison M. Dunning,^{1,99,*} and Stacey L. Edwards^{2,99,*}

SNPs with $r^2 > 0.9$ ($n = 184$), but we managed to include 563 SNPs with a designability score (DS) > 0.9 and which passed QC.⁶ IMPUTE v.2.0 was used to impute genotypes of all known SNPs in the region using the 1000 Genome Project data (March 2012 version) as a reference panel.

Case-control analyses were conducted on 3,365 SNPs (563 genotyped and 2,776 imputed at $r^2 > 0.3$). In European-ancestry women, 461 of these SNPs were associated with overall breast cancer risk, 489 with ER⁺ and 38 with ER⁻ breast cancer risk ($p < 10^{-4}$; Table S1). SNP rs10941679 showed the strongest overall association (MAF = 0.27, per-minor (g) allele: OR = 1.12; 95% CI 1.10–1.14; $p = 2.55 \times 10^{-26}$; Figure 1, Tables 1 and S1). To identify additional association signals at this region, we conducted a forward stepwise logistic regression examining SNPs with univariate $p < 0.1$ ($n = 1,040$).⁶ The most parsimonious model included three variants: SNP1 rs10941679 (signal 1), SNP2 rs6864776 (signal 2; conditional $p = 6.22 \times 10^{-11}$), and SNP3 rs200229088 (signal 3; conditional $p = 1.12 \times 10^{-5}$, borderline significance; Table S2). SNP1 and SNP3 are weakly correlated ($r^2 = 0.15$) but SNP2 was uncorrelated with the other two ($r^2 = 0.07$ and 0.05).

The top signal, SNP1 rs10941679, is markedly more significant than any other SNP in the locus (likelihood ratio $> 10,000:1$). Hence, the most parsimonious explanation is that this SNP is causally related to risk. The next most strongly associated SNP, after adjustment for signal 1 SNP rs10941679, was rs6864776, representing signal 2 (OR per minor allele = 1.04; 95% CI 1.02–1.06; $p = 7.84 \times 10^{-4}$; conditional $p = 1.44 \times 10^{-12}$). Within signal 2, a further 37 SNPs correlated with rs6864776 at $r^2 > 0.6$, had likelihood ratios of $<100:1$ relative to rs6864776, and hence could not be excluded from being causative

statistically (Table S2). After adjustment for both signal 1 SNP rs10941679 and signal 2 top SNP rs6864776, a single SNP remained: rs200229088 (OR overall = 1.09, 95% CI 1.07–1.12; $p = 2.28 \times 10^{-12}$; conditional $p = 1.12 \times 10^{-5}$). There are no other SNPs correlated with rs200229088 that could explain this association. All other SNPs were excluded from causality (likelihood ratio $> 10,000:1$; Table S2). Two of the excluded variants had been previously postulated as likely causative variants^{4,7} and so we investigated these in more depth. We found both SNPs to be partially correlated with all three signals and consequently display initially inflated effects, which are adjusted by the conditional analyses. Thus, SNP rs4415084⁴ (r^2 with signal 1 SNP rs10941679 = 0.51, with signal 2 SNP rs6864776 = 0.11, and with signal 3 SNP rs200229088 = 0.37) has odds against causality > 10 million:1 versus signal 1 candidate rs10941679. Similarly, SNP rs7716600, which is an eQTL for MRPS30 expression⁷ (r^2 with SNP rs10941679 = 0.77, with SNP rs6864776 = 0.05, and with SNP rs200229088 = 0.12) has odds against causality $>160,000:1$ versus signal 1 candidate rs10941679. These exclusions of former causal candidates highlight the need for fine-mapping studies before conducting functional analyses.

Haplotype analyses were conducted using the above three signal-representative variants, which generated eight haplotypes (Table 2). Haplotypes carrying the rare allele of signal 3 SNP rs200229088 conferred higher risks than corresponding haplotypes carrying the common allele, consistent with this allele having an independent effect. Haplotype G, carrying the minor alleles of both the signal 1 and 2 representative SNPs, is very rare and reveals that their risk alleles are negatively correlated, which is also consistent with our finding that signal 2 top SNP

Genetics, National Cancer Institute, Rockville, MD 20850, USA; ⁷⁶Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh Medical School, Edinburgh EH8 9AG, UK; ⁷⁷Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 17177 Stockholm, Sweden; ⁷⁸Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, 3008 AE Rotterdam, the Netherlands; ⁷⁹Department of Surgical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, 3008 AE Rotterdam, the Netherlands; ⁸⁰Shanghai Municipal Center for Disease Control and Prevention, 200336 Shanghai, China; ⁸¹Sheffield Cancer Research, Department of Oncology and Metabolism, University of Sheffield, Sheffield S10 2RX, UK; ⁸²Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield S10 2HQ, UK; ⁸³Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 110-799, Korea; ⁸⁴Cancer Research Institute, Seoul National University, Seoul 110-799, Korea; ⁸⁵Department of Preventive Medicine, Seoul National University College of Medicine, Seoul 110-799, Korea; ⁸⁶Saw Swee Hock School of Public Health, National University of Singapore, Singapore 117597, Singapore; ⁸⁷Department of Surgery, National University Health System, Singapore 117597, Singapore; ⁸⁸Institute of Human Genetics, Pontificia Universidad Javeriana, Bogota, DC 11001000, Colombia; ⁸⁹Department of Genetics and Pathology, Pomeranian Medical University, 70-115 Szczecin, Poland; ⁹⁰National Cancer Institute, Bangkok 10400, Thailand; ⁹¹International Agency for Research on Cancer, Lyon Cedex 08, France; ⁹²School of Public Health, China Medical University, Taichung 40402, Taiwan; ⁹³Taiwan Biobank, Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan; ⁹⁴Department of Surgery, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung 812, Taiwan; ⁹⁵Division of Genetics and Epidemiology, The Institute of Cancer Research, London SM2 5NG, UK; ⁹⁶Genomics Center, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Québec City, QC G1V 4G2, Canada; ⁹⁷Department of Clinical Molecular Biology, Oslo University Hospital, University of Oslo, 0450 Oslo, Norway

⁹⁸These authors contributed equally to this study

⁹⁹These authors contributed equally to this study

*Correspondence: amd24@medschl.cam.ac.uk (A.M.D.), stacey.edwards@qimrberghofer.edu.au (S.L.E.)

<http://dx.doi.org/10.1016/j.ajhg.2016.07.017>




Figure 1. Manhattan Plot of the 5p12 Breast Cancer Susceptibility Locus

SNPs are plotted according to their chromosomal position on the x axis and their overall p values (\log_{10} values, likelihood ratio test) from the European BCAC studies (48,155 case and 43,612 control subjects) on the y axis. The purple dotted line intersects the y axis at $p = 10^{-8}$ and indicates genome-wide significance. Candidate SNPs in signal 1 (rs10941679), signal 2 (38 SNPs), and signal 3 (rs200229088) are shown as short vertical lines. The locations of annotated genes and putative lncRNA transcripts from GENCODE and enhancers predicted in Corradin et al.¹³ and Hnisz et al.¹² from breast cancer cell lines are shown in the bottom panels.

rs6864776 increases in significance after conditioning on signal 1 SNP rs10941679 (Table 1).

We examined the associations of these three SNPs in the Asian case-control studies within BCAC. SNP1 and SNP3 both replicated in the Asian studies and the relative risk estimates with overall breast cancer were consistent with those seen in the European population: per *g*-allele OR (rs10941679) = 1.09; 95% CI 1.04–1.15; $p = 0.0009$, conditional $p = 0.0859$ and per *t*-allele OR (rs200229088) = 1.09;

95% CI 1.02–1.15; $p = 0.0065$, conditional $p = 0.9149$ (Table 1). SNP2 was not replicated in Asians (per *a*-allele OR = 0.94; 95% CI 0.89–1.00; $p = 0.034$, conditional $p = 0.8901$) (Table 1).

We investigated the associations of these three signals with tumor subtypes based on ER status. SNP1 rs10941679 was largely associated with ER⁺ breast cancer (OR ER⁺ = 1.15; 95% CI 1.13–1.18; $p = 8.35 \times 10^{-30}$ versus OR ER⁻ disease = 1.04; 95% CI 1.00–1.08; $p = 0.059$;

Table 1. Associations of the Top SNPs from Each Signal with Overall Breast Cancer Risk and Breast Cancer Stratified by ER Status

Sig	SNP	Com	Min	MAF*	OR Overall		Conditional p Value	OR ER ⁻	p ER ⁻	OR ER ⁺	p ER ⁺
					95% CI	p Overall					
Europeans											
1	rs10941679	A	G	0.27	1.12 (1.10–1.14)	2.55×10^{-26}	6.55×10^{-24}	1.04 (1–1.08)	0.059	1.15 (1.13–1.18)	8.35×10^{-30}
2	rs6864776	G	A	0.23	1.04 (1.02–1.06)	7.84×10^{-4}	1.44×10^{-12}	1.10 (1.05–1.14)	2.5×10^{-5}	1.02 (0.99–1.05)	0.08
3	rs200229088	TTG	T	0.31	1.09 (1.07–1.12)	2.28×10^{-12}	1.12×10^{-5}	1.03 (0.99–1.09)	0.11	1.12 (1.09–1.15)	7.51×10^{-14}
Asians											
1	rs10941679	A	G	0.50	1.09 (1.04–1.15)	9.12×10^{-4}	0.0859	1.03 (0.95–1.11)	0.53	1.11 (1.04–1.18)	1.32×10^{-3}
2	rs6864776	G	A	0.32	0.94 (0.89–1.00)	3.47×10^{-2}	0.8901	0.95 (0.87–1.04)	0.28	0.94 (0.89–1.00)	6.24×10^{-2}
3	rs200229088	TTG	T	0.37	1.09 (1.02–1.15)	6.52×10^{-3}	0.9149	1.04 (0.95–1.14)	0.43	1.08 (1.00–1.16)	3.65×10^{-2}

Abbreviations are as follows: Com, common alleles; Min, minor alleles; MAF, minor allele frequency; OR, per-allele odds ratios (OR); 95% CI, 95% confidence intervals and 1 degree of freedom; p, significance levels for overall breast cancer are indicated in European and Asian case-control studies, and separately for ER⁺ and ER⁻ disease.

Table 2. Haplotype Analysis across the BCAC Studies

Haplotypes	rs10941679 Signal 1	rs6864776 Signal 2	rs200229088 Signal 3	Haplotype Frequency	OR	p Value
A	1	1	1	0.395440	–	–
B	1	1	2	0.120099	1.06 (1.02–1.10)	1.49×10^{-3}
C	1	2	1	0.199599	1.10 (1.06–1.13)	7.76×10^{-11}
D	1	2	2	0.018665	1.15 (1.04–1.27)	5.03×10^{-3}
E	2	1	1	0.098169	1.14 (1.09–1.19)	1.45×10^{-11}
F	2	1	2	0.154525	1.20 (1.16–1.24)	2.72×10^{-30}
G	2	2	1	0.004248	0.91 (0.72–1.15)	4.15×10^{-1}
H	2	2	2	0.009253	1.28 (1.10–1.48)	1.14×10^{-3}

Each haplotype was compared to the ancestral haplotype carrying the common alleles of signal 1 SNP rs10941679, signal 2 SNP rs6864776, and signal 3 SNP rs200229088 (haplotype A).

p heterogeneity = 1.5×10^{-5} ; Table 1) as was SNP3 rs200229088 (OR ER⁺ = 1.12; 95% CI 1.09–1.15; p = 7.51×10^{-14} versus OR ER⁻ = 1.03; 95% CI 0.99–1.09; p = 0.11, p heterogeneity = 0.02). By contrast, SNP2 rs6864776 was moderately associated with ER⁻ but not ER⁺ tumors (OR ER⁻ = 1.10; 95% CI 1.05–1.14; p = 2.55×10^{-5} versus OR ER⁺ = 1.02; 95% CI 0.99–1.05; p = 0.08; p heterogeneity = 0.01; Table 1).

Candidate SNPs 1–3 span a 1.7 Mb region on 5p12 that includes three annotated genes—*FGF10* (MIM: 602115), *MRPS30* (MIM: 611991), and *HCN1* (MIM: 602780)—and several putative long noncoding RNAs (lncRNAs; Figure 1). To identify potential target gene(s), we examined the associations of the three lead SNPs with expression levels of genes located within 1 Mb in three different studies: (1) 116 normal breast samples and 241 breast tumors from the Norwegian Breast Cancer Study (NBCS),⁸ (2) 93 normal and 765 breast cancer tissues from the TCGA study (germline genotype data from Affymetrix SNP 6 array were obtained from TCGA dbGAP data portal⁹), and (3) 183 normal breast samples from the Genotype-Tissue Expression (GTEx) project.¹⁰ The SNP1 rs10941679 risk-associated *g*-allele was moderately associated with increased *FGF10* mRNA expression in NBCS normal breast (p = 0.013, p corrected = 0.39) and breast tumors (p = 0.005, p corrected = 0.38) as well as in GTEx normal breast (p corrected = 0.02; Figures 2A and S1A). The effect in TCGA was in the same direction, though not significant (normal breast p = 0.353, p corrected = 0.95 and breast tumors p = 0.057, p corrected = 0.41; Figure S1B). The *g*-allele was also associated with increased expression of *MRPS30* in the NBCS normal (p = 0.002, p corrected = 0.36) and breast tumors (p = 0.049, p corrected = 0.43), in GTEx normal breast (p corrected = 0.002), and in TCGA (normal breast p = 6.86×10^{-5} , p corrected = 5.31×10^{-3} and breast tumors p = 7.21×10^{-6} , p corrected = 9.35×10^{-4} ; Figures 2B, S1A, and S1C). No associations were observed with SNP2 rs6864776 or SNP3 variant rs200229088. We also measured endogenous levels of *FGF10*, *MRPS30*, and nearby lncRNAs *FGF10-AS1*,

BRCAT54, *RP11-503D12.1*, and *RP11-473L15.3* mRNA in breast cell lines homozygous (A/A or G/G) or heterozygous (A/G) for the common allele of SNP1 (Table S3, Figures 2C, 2D, S2, and S3). Total RNA from cell lines was extracted using Trizol and complementary DNA synthesized using random primers as per manufacturers' instructions. Quantitative PCR (qPCR) were performed using TaqMan assays for *FGF10* and *MRPS30* normalized against beta-glucuronidase (*GUSB* [MIM: 611499]) or with SYTO9 for lncRNAs normalized against TATA box-binding protein (*TBP* [MIM: 600075]); primers are listed in Table S4). Although the number of ER⁺ breast cell lines carrying the risk allele was limited, *FGF10* and *MRPS30* mRNA levels were significantly higher in the BT474 heterozygous cell line (Figures 2C and 2D). *BRCAT54* was detected in the majority of cell lines but its expression appears to be genotype independent (Figure S3A). *FGF10-AS1*, *RP11-503D12.1*, and *RP11-473L15.3* transcripts were either expressed at very low levels or not detected in the cell lines analyzed (Figures S3B–S3D). Therefore, although we cannot rule out the possibility that the risk SNPs may influence local lncRNA expression, the low or absent transcript levels precluded any further evaluation.

Candidate causal SNPs were then explored using publicly available datasets from ENCODE,¹¹ which includes information such as the location of promoter and enhancer histone marks, open chromatin, bound proteins, and altered motifs for the MCF7 breast cancer cell line, and from Hnisz et al.¹² and Corradin et al.¹³ to identify the location of likely enhancers and their gene targets in a cell-specific context. Analysis of *cis* enhancer-gene interactions via PreSTIGE¹³ showed evidence of putative regulatory elements (PREs) surrounding the top risk-associated SNPs in MCF7 breast cancer cells, but no histone-marked elements harboring a risk SNP in this cell line or in a range of cell lines and tissues analyzed in Roadmap (Figures 1 and S4). However, it is possible that certain epigenetic marks may be detected only in a specific cell subtype such as breast stem cells or in response to an external stimulus.




Figure 2. Association of rs10941679 with *FGF10* and *MRPS30* Expression in Normal Breast Tissues, Breast Tumors, and Breast Cancer Cell Lines

(A and B) *FGF10* (A) or *MRPS30* (B) expression in normal breast ($n = 116$) or breast tumors from NBBCS dataset ($n = 241$). SNP genotypes are shown on the x axis and log₂-normalized gene expression values on the y axis. p values are presented before and after correction for multiple testing using FDR as implemented in p.adjust function in R. Each box plot shows the median rank normalized gene expression (horizontal line), the first through third quartiles (box), and 1.5× the interquartile range (whiskers).

(C and D) Endogenous *FGF10* (Hs00610298_m1) (C) or *MRPS30* (Hs00169612_m1) (D) expression measured by qPCR in untreated breast cell lines and normalized to *GUSB* (4326320E). Error bars denote SEM ($n = 3$). p values were determined with a two-tailed t test. ** $p < 0.01$, *** $p < 0.001$.

To identify target gene(s), we performed chromatin conformation capture (3C) assays in ER⁺ MCF7, BT474, and MDA-MB-361 and ER⁻ MDA-MB-231 breast cancer cell lines and Bre80 normal breast cells (Table S5).⁸ 3C libraries were created by cross-linking the chromatin from cell lines; DNA was then digested with EcoRI, which flanks 12 contiguous fragments that cover the PRE, and the *FGF10*, *MRPS30*, and *HCN1* promoters (Table S6); DNA was religated and decrosslinked; and qPCR with primers for the bait (gene promoters) and interactors (12 PRE fragments) was performed to detect the presence of ligation products, representing gene loops. BAC clones covering the regions of interest were used to normalize for PCR efficiency. These assays showed that the PRE containing SNP1 frequently interacted with the *FGF10* and *MRPS30* promoter regions in MCF7 and BT474 breast cancer cell lines, but only with *MRPS30* in the MDA-MB-361, MDA-MB-231, and Bre80 cell lines. This latter result was expected because *FGF10* is not expressed or expressed at very low levels in these cell lines (Figures 2C, 3A, S5, and S6). Notably, both genes share a bidirectional promoter with the lncRNAs *FGF10-AS1* and *BRCAT54*, raising the

possibility that these transcripts are also targets of the PRE (Figure 3A). No additional interactions were detected between the PRE and other annotated genes within 1 Mb of the PRE, including *HCN1* (Figure S5). To assess the potential impact of SNP1 on the identified chromatin interactions, allele-specific 3C was performed in heterozygous BT474 cell lines.⁸ However, the sequence profiles revealed that SNP1 had no significant effect on chromatin looping (Figure S7).

The regulatory capability of the PRE, combined with the effect of SNP1, was further examined in reporter assays. Promoter-driven luciferase reporter constructs were generated by the insertion of PCR-amplified fragments containing *FGF10*, *FGF10-AS1*, *MRPS30*, or *BRCAT54* promoters into pGL3-Basic.¹⁴ A 1,736-bp PRE fragment (containing either the common or minor allele of rs10941679) was then generated by PCR and cloned downstream of the modified pGL3-promoter constructs (Table S7). MCF7 and BT474 breast cancer cell lines plus Bre80 normal breast cells were transfected with the reporter plasmids and luciferase activity was measured 24 hr after transfection. To correct for any differences in transfection efficiency or




Figure 3. Distal Regulation of *FGF10* and *MRPS30* at the 5p12 Risk Region

(A) 3C interaction profiles between the *FGF10/FGF10AS-1* or *MRPS30/BRCAT54* bidirectional promoters and the putative regulatory element (PRE; gray bar) containing SNP rs10941679. Anchor points are set at the promoters. Graphs represent one of three independent experiments (see Figure S5B). Error bars denote SD.

(B) Luciferase reporter assays after transient transfection of ER⁺ BT474 breast cancer cell lines. The PRE containing the major SNP allele was cloned downstream of target gene promoter-driven luciferase constructs (Ref PRE). The risk *g*-allele was engineered into the constructs and designated by the rs ID. Primers are listed in Table S7. Error bars denote 95% confidence intervals from three independent experiments. *p* values were determined by 2-way ANOVA followed by Dunnett's multiple comparisons test (***p* < 0.001).

(C) EMSA for oligonucleotides containing SNP rs1094617 with the A = common allele and G = minor allele as indicated below the panel, assayed using BT474 nuclear extracts. Primers are listed in Table S8. Labels above each lane indicate inclusion of competitor oligonucleotides at 30- and 100-fold molar excess, respectively: (-) no competitor and control denotes a non-specific competitor. A red arrowhead shows a band of different mobility detected between the common and minor alleles.

cell lysate preparation, *Firefly* luciferase activity was normalized to *Renilla*. Notably, the "Ref PRE" acted as a transcriptional enhancer, leading to a 2- to 3-fold increase in *FGF10*, *MRPS30*, and *BRCAT54* promoter activity, but had no effect on the *FGF10-AS1* promoter in MCF7 and BT474 cells (Figures 3B and S8). The enhancer activity was also observed for the *MRPS30* and *BRCAT54* promoters in Bre80 cells (Figure S8). In all cell lines, inclusion of the SNP1 risk (*g*) allele had no significant effect on the PRE enhancer activity. Although this appears to rule out an effect of this SNP on transactivation, it is possible that SNP1 affects the recruitment of key proteins required for the epigenetic modification of the enhancer, which would not be observed in a reporter assay. Another possibility is that the SNP effect may be observed only under certain biological conditions such as growth factor stimulation.

To seek further evidence that SNP1 lies within an enhancer element, we performed electrophoretic mobility

shift assays (EMSA) for both the protective (*a*) and risk (*g*) alleles.¹⁵ Nuclear lysates were prepared from ER⁺ BT474, MCF7, and MDA-MB-361 or ER⁻ MDA-MB-231 and Hs578T cells using the NE-PER nuclear and cytoplasmic extraction reagents. Biotinylated oligonucleotide duplexes were prepared by combining sense and antisense oligonucleotides, heat annealing, and slow cooling. Duplex-bound complexes were transferred onto Zeta-Probe positively charged nylon membranes by semi-dry transfer then cross-linked onto the membranes. Membranes were processed with the LightShift Chemiluminescent EMSA kit as per the manufacturer's instructions, and signals were visualized with the C-DiGit blot scanner. For SNP1, we observed allele-specific binding by nuclear proteins only in the ER⁺ BT474, MCF7, and MDA-MB-361 extracts (Figures 3C and S9). The protein-DNA complexes were shown to be specific, as demonstrated by increasing amounts of cold self-competitor (Figures 3C and S9 and Table S8).

Further EMSAs using competitor DNA or antibody supershifts against predicted transcription factors (TFs) suggested four proteins bound to the SNP site including FOXA1, FOXA2, CEBPB, and OCT1 (Figure S10 and Table S9). To confirm TF binding in vivo, we performed chromatin immunoprecipitation (ChIP) in heterozygous BT474 cells as previously described (Table S10).¹⁵ When compared to an IgG control antibody, we observed a moderate enrichment in FOXA1 and OCT1 binding to DNA overlapping SNP rs10941679, but no difference between alleles in this cell line (Figure S11). In addition, western blot analysis indicated that FOXA1 protein expression was restricted to the ER⁺ breast cancer cell lines analyzed, whereas OCT1 was more widely expressed (Figure S12). FOXA1 is a pioneer factor and master regulator of ER activity due to its ability to open local chromatin and recruit ER to target gene promoters.¹⁶ Notably, breast cancer-associated SNPs are enriched for FOXA1 binding¹⁷ and several studies have linked cooperative binding of FOXA1, ER, and OCT1 to increased gene transcription.^{18,19} Consistent with our eQTL data, it is tempting to speculate that in specific ER⁺ cell subtypes and/or conditions, rs10941679 alters FOXA1 affinity and OCT1 recruitment leading to target gene activation.

In conclusion, we have provided evidence for at least three independent causal SNPs with effects on the risk of breast cancer at this locus. The minor *g*-allele of signal 1 SNP rs10941679 conferred a 15% increased risk of ER⁺ breast cancer and higher expression levels of the *MRPS30* and *FGF10* genes and was the most strongly associated SNP with *MRPS30* expression in this 1 Mb region. *MRPS30*—also called *PDCD9* (Programmed Cell Death protein 9)—encodes a mitochondrial ribosomal protein involved in apoptosis.²⁰ Although the role of mitochondria in apoptosis remains unclear, it is well established that cytochrome *c* and other pro-apoptotic proteins are released during cell death initiation.²⁰ Clearly, further investigation of the function of this protein is now merited. By contrast, *FGF10* is an extensively studied gene with compelling data suggesting its involvement in breast tumorigenesis. *FGF10* is a member of the fibroblast growth factor (FGF) family and encodes a glycoprotein that specifically binds to *FGFR2* (splice *FGFR2IIIb*) to control signaling pathways including cell differentiation, proliferation, and apoptosis.²¹ Variants regulating *FGFR2* (MIM: 176943) have the strongest association with ER⁺ breast cancer susceptibility identified to date.²² *FGF10* is overexpressed in ~10% of human breast cancers²³ and increased levels of *FGF10* are highly correlated with proliferation rate of breast cancer cell lines and cancer cell invasion.^{24,25} It signals through multiple downstream pathways including MAPK and WNT and genes such as *FGFR2*, *CCND1* (MIM: 168461), and *TGFBI* (MIM: 190180),^{21,24} all known to play key roles in breast cancer. Therapeutic targeting of FGFs and their receptors (FGFRs) is currently a major area of drug development research, and the identification of a subgroup of individuals diag-

nosed with breast cancer with alterations in these pathways may open new avenues for personalized medicine and pathway-targeted treatments.

Supplemental Data

Supplemental Data include Supplemental Acknowledgments, 12 figures, 10 tables, and consortia information and can be found with this article online at <http://dx.doi.org/10.1016/j.ajhg.2016.07.017>.

Received: January 27, 2016

Accepted: July 16, 2016

Published: September 15, 2016

Web Resources

1000 Genomes, <http://www.1000genomes.org>
Cancer Cell Line Encyclopedia (CCLE), <https://portals.broadinstitute.org/ccle/home>
ENCODE, <https://www.encodeproject.org/>
GEO, <http://www.ncbi.nlm.nih.gov/geo/>
GTEx Portal, <http://www.gtexportal.org/home/>
OMIM, <http://www.omim.org/>
PreSTIGE, <http://genetics.case.edu/prestige/>
The Cancer Genome Atlas, <http://cancergenome.nih.gov/>

References

1. Stacey, S.N., Manolescu, A., Sulem, P., Rafnar, T., Gudmundsson, J., Gudjonsson, S.A., Masson, G., Jakobsdottir, M., Thorlacius, S., Helgason, A., et al. (2007). Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. *Nat. Genet.* 39, 865–869.
2. Easton, D.F., Pooley, K.A., Dunning, A.M., Pharoah, P.D., Thompson, D., Ballinger, D.G., Struwing, J.P., Morrison, J., Field, H., Luben, R., et al.; SEARCH collaborators; kConFab; AOCs Management Group (2007). Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature* 447, 1087–1093.
3. Hunter, D.J., Kraft, P., Jacobs, K.B., Cox, D.G., Yeager, M., Hankinson, S.E., Wacholder, S., Wang, Z., Welch, R., Hutchinson, A., et al. (2007). A genome-wide association study identifies alleles in *FGFR2* associated with risk of sporadic postmenopausal breast cancer. *Nat. Genet.* 39, 870–874.
4. Stacey, S.N., Manolescu, A., Sulem, P., Thorlacius, S., Gudjonsson, S.A., Jonsson, G.F., Jakobsdottir, M., Bergthorsson, J.T., Gudmundsson, J., Aben, K.K., et al. (2008). Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. *Nat. Genet.* 40, 703–706.
5. Milne, R.L., Goode, E.L., García-Closas, M., Couch, F.J., Severi, G., Hein, R., Fredericksen, Z., Malats, N., Zamora, M.P., Arias Pérez, J.I., et al.; GENICA Network; kConFab Investigators; AOCs Group (2011). Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. *Cancer Epidemiol. Biomarkers Prev.* 20, 2222–2231.
6. Michailidou, K., Hall, P., Gonzalez-Neira, A., Ghoussaini, M., Dennis, J., Milne, R.L., Schmidt, M.K., Chang-Claude, J., Bojesen, S.E., Bolla, M.K., et al.; Breast and Ovarian Cancer Susceptibility Collaboration; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON); kConFab

- Investigators; Australian Ovarian Cancer Study Group; GENICA (Gene Environment Interaction and Breast Cancer in Germany) Network (2013). Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nat. Genet.* *45*, 353–361, e1–e2.
7. Quigley, D.A., Fiorito, E., Nord, S., Van Loo, P., Alnæs, G.G., Fleischer, T., Tost, J., Moen Volland, H.K., Tramm, T., Overgaard, J., et al. (2014). The 5p12 breast cancer susceptibility locus affects MRPS30 expression in estrogen-receptor positive tumors. *Mol. Oncol.* *8*, 273–284.
 8. Ghossaini, M., Edwards, S.L., Michailidou, K., Nord, S., Cowper-Sal Lari, R., Desai, K., Kar, S., Hillman, K.M., Kaufmann, S., Glubb, D.M., et al.; Australian Ovarian Cancer Management Group; Australian Ovarian Cancer Management Group (2014). Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. *Nat. Commun.* *4*, 4999.
 9. Li, Q., Seo, J.H., Stranger, B., McKenna, A., Pe'er, I., Laframboise, T., Brown, M., Tyekucheva, S., and Freedman, M.L. (2013). Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. *Cell* *152*, 633–641.
 10. Consortium, G.T.; GTEx Consortium (2013). The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* *45*, 580–585.
 11. Birney, E., Stamatoyannopoulos, J.A., Dutta, A., Guigó, R., Gingeras, T.R., Margulies, E.H., Weng, Z., Snyder, M., Dermitzakis, E.T., Thurman, R.E., et al.; ENCODE Project Consortium; NISC Comparative Sequencing Program; Baylor College of Medicine Human Genome Sequencing Center; Washington University Genome Sequencing Center; Broad Institute; Children's Hospital Oakland Research Institute (2007). Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. *Nature* *447*, 799–816.
 12. Hnisz, D., Abraham, B.J., Lee, T.I., Lau, A., Saint-André, V., Sigova, A.A., Hoke, H.A., and Young, R.A. (2013). Super-enhancers in the control of cell identity and disease. *Cell* *155*, 934–947.
 13. Corradin, O., Saiakhova, A., Akhtar-Zaidi, B., Myeroff, L., Willis, J., Cowper-Sal Lari, R., Lupien, M., Markowitz, S., and Scacheri, P.C. (2014). Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits. *Genome Res.* *24*, 1–13.
 14. Glubb, D.M., Maranian, M.J., Michailidou, K., Pooley, K.A., Meyer, K.B., Kar, S., Carlebur, S., O'Reilly, M., Betts, J.A., Hillman, K.M., et al.; GENICA Network; kConFab Investigators; Norwegian Breast Cancer Study (2015). Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. *Am. J. Hum. Genet.* *96*, 5–20.
 15. Dunning, A.M., Michailidou, K., Kuchenbaecker, K.B., Thompson, D., French, J.D., Beesley, J., Healey, C.S., Kar, S., Pooley, K.A., Lopez-Knowles, E., et al.; EMBRACE; GEMO Study Collaborators; HEBON; kConFab Investigators (2016). Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nat. Genet.* *48*, 374–386.
 16. Hurtado, A., Holmes, K.A., Ross-Innes, C.S., Schmidt, D., and Carroll, J.S. (2011). FOXA1 is a key determinant of estrogen receptor function and endocrine response. *Nat. Genet.* *43*, 27–33.
 17. Cowper-Sal Lari, R., Zhang, X., Wright, J.B., Bailey, S.D., Cole, M.D., Eeckhoute, J., Moore, J.H., and Lupien, M. (2012). Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. *Nat. Genet.* *44*, 1191–1198.
 18. Meyer, K.B., Maia, A.T., O'Reilly, M., Teschendorff, A.E., Chin, S.F., Caldas, C., and Ponder, B.A. (2008). Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. *PLoS Biol.* *6*, e108.
 19. Belikov, S., Astrand, C., and Wrangé, O. (2009). FoxA1 binding directs chromatin structure and the functional response of a glucocorticoid receptor-regulated promoter. *Mol. Cell. Biol.* *29*, 5413–5425.
 20. Cavdar Koc, E., Ranasinghe, A., Burkhart, W., Blackburn, K., Koc, H., Moseley, A., and Spremulli, L.L. (2001). A new face on apoptosis: death-associated protein 3 and PDCD9 are mitochondrial ribosomal proteins. *FEBS Lett.* *492*, 166–170.
 21. Turner, N., and Grose, R. (2010). Fibroblast growth factor signalling: from development to cancer. *Nat. Rev. Cancer* *10*, 116–129.
 22. Meyer, K.B., O'Reilly, M., Michailidou, K., Carlebur, S., Edwards, S.L., French, J.D., Prathalingham, R., Dennis, J., Bolla, M.K., Wang, Q., et al.; GENICA Network; kConFab Investigators; Australian Ovarian Cancer Study Group (2013). Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. *Am. J. Hum. Genet.* *93*, 1046–1060.
 23. Theodorou, V., Boer, M., Weigelt, B., Jonkers, J., van der Valk, M., and Hilken, J. (2004). Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. *Oncogene* *23*, 6047–6055.
 24. Abolhassani, A., Riaz, G.H., Azizi, E., Amanpour, S., Muhammadnejad, S., Haddadi, M., Zekri, A., and Shirkoohi, R. (2014). FGF10: type III epithelial mesenchymal transition and invasion in breast cancer cell lines. *J. Cancer* *5*, 537–547.
 25. Chioni, A.M., and Grose, R. (2009). Negative regulation of fibroblast growth factor 10 (FGF-10) by polyoma enhancer activator 3 (PEA3). *Eur. J. Cell Biol.* *88*, 371–384.